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Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved and others are
under development.
Results: The aims of this study were to illustrate natural polymorphisms in the HCV protease and measure the
frequency of PI resistance mutations in different HCV genotypes from PI-naïve patients.
Direct sequencing of HCV NS3/4A protease was performed in 156 HCV patients naïve to PIs who were infected
with genotype 1a (n = 31), 1b (n = 39), 2 (n = 30), 3 (n = 33) and 4 (n = 23).
Amino acid (aa) substitutions associated with HCV PI resistance were found in 17/156 (10.8%) sequences. Mutations
V36L, T54S, V55A/I, and Q80K/L were observed in 29% of patients with genotype 1a, and V55F, Q80L/N and M175L
in 10% of patients with genotype 1b. The mutation V158M was found in 3% of patients with genotype 2, D168Q
was present in 100% of patients with genotype 3 and D168E was observed in 13% of patients with genotype 4. In
addition, multiple aa polymorphisms not associated with PI resistance were detected in patients with genotypes 1a,
1b and 4.
Conclusions: Although major PI resistance mutations were not detected, other resistance mutations conferring low
level resistance to PIs together with a number of natural polymorphisms were observed in proteases of PI naïve
HCV patients. A more extensive analysis is needed to better evaluate the impact of baseline resistance and
compensatory mutations in the efficacy of HCV PI treatment.
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Hepatitis C virus (HCV) infects more than 170 million
people worldwide [1]. Treatment with pegylated inter-
feron-α and ribavirin is burdened by adverse reactions in
a significant proportion of patients [2] and a sustained
virological response is achieved in only 50% of patients
infected with genotype 1 [3] and 80% of patients infected
with genotype 2 [4]. Recently, inhibitors of HCV non-
structured serine –protease 3 (NS3/4A) have been
approved (Telaprevir, Boceprevir), and others are under
development (TMC435350, ITMN191, SCH900518,
MK7009, BI-201335, MK5172, GS-9256, ABT 45, BMS-
791325 and ACH-1625) [5-9]. However, selection of
drug-resistant HCV variants has already been reported* Correspondence: f.baldanti@smatteo.pv.it
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reproduction in any medium, provided the orin protease inhibitor (PI)-treated individuals [7-14]. The
degree of resistance appears to be related both to muta-
tions at specific NS3 positions and to changes in amino
acid (aa) residues [5,7,15].
The high HCV replication rate and lack of a proof-
reading mechanism determine a natural variability,
which promotes the rapid emergence of drug-resistant
variants [15]. Natural aa changes in NS3 associated with
reduced drug susceptibility have been observed in treat-
ment naïve patients [10,16,17]. However, the clinical im-
pact of baseline resistance and its influence on the
ability of the virus to replicate in vivo remain unclear
[15,16]. Recently, the sporadic transmission of naturally
occurring NS3 resistance mutations was reported [16].
In addition, the impact of the frequency of baseline
HCV PI resistance mutations in HIV/HCV co-infected
patients with respect to HCV mono-infected patients is
still debated [17-19]. The frequency of naturallyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ance in treatment naïve HCV patients infected with gen-
otypes 1, 2, 3 and 4 was investigated.
Materials and methods
HCV PI-naive patients referred to our hospital between
2010 and 2011 were included in the study. Patients were
stratified according to HCV genotype and a comparable
number of patients infected with HCV genotypes 1a, 1b,
2, 3 and 4 were sequentially enrolled in the study. Most
(75%) were treated with pegylated Interferon-α and
Ribavirin, while none had ever been treated with a PI for
hepatitis C. For NS3 sequencing, surplus serum samples
were prospectively collected from each patient. HCV
genotypes were defined using the Versant HCV Geno-
type 2.0 Assay LiPA (Siemens Healthcare Diagnostic
Inc., Tarrytown, NY USA). The NS3 region was
sequenced to further subtype HCV strains and identify
genotypes 1a/1b. Data were analyzed with the Blast pro-
gram (http://blast.ncbi.nlm.nih.gov). The study was
approved by the Ethics Committee of the Fondazione
IRCCS Policlinico San Matteo (protocol no. 20080009620).
Informed consent was obtained from all subjects prior to
enrollment.
Viral RNA was extracted from serum samples using
the automatic Easy Mag extractor (Biomerieux, Lyon,
France), and full-length HCV NS3/4A sequences were
amplified using a nested RT-PCR. In detail, the primers
used respectively in PCR and nested PCR, spanning
NS3/4A aa from 1 to 181, were as follows: 1a-Forward
outer 50-GACATCATCAACGGCTTGCCCG-30 and 1a-
Reverse outer 50-GAGTACGTGATGGGGCTGCCAG-30,
1a-Forward inner 50-GGAATGGTCTCCAAGGGGTG
GA-30 and 1a-Reverse inner 50-CATGGGCCTTGGA
CATGTAAGC-30 for genotype 1a; 1b-Forward outer 50-




genotype 1b; 2abc-Forward outer 50-GGCACHTAYATC
TATGACCA-30 and 2-Reverse outer 50-CAGYCCRATG
GAGARGAARGTCA-30, 2-Forward inner 50-GTYCTRA
TGTTGGGRTTGATBCC-30 and 2-Reverse inner 50-
TASGCCCCAAAMCCMAGSGTGG-30 for genotype 2; 3-
Forward outer 50-GTCTCTGCRCGATTAGGCCGTGA-30
and 3-Reverse outer 50-CAGTTTRGCACCAGTTGTAA
CG-30, 3-Forward inner 50-GTTGGGACCTGCTGATG
ACTA-30 and 3-Reverse inner 50-CCCAGTGCGGAT
GTTGGGGT-30 for genotype 3; finally, 4-Forward outer
50-GGGYAATGARATMYTGCTCGG-30 and 4-Reverse
outer 50-GCCAGGAACTTMCCRTABGT-30, 4-Forward
inner 50-GGAGRCTBCTYGCBCCCAT-30 and 4-Reverse
inner 50-GAGTAYGTGATYGGCGC-30 for genotype 4.
The PCR products in the first round were obtained byusing the following conditions: 15’ at 45°C for the reverse
transcription followed by 10’ at 94°C, and then 50 cycles at
94°C for 1’, 55°C for 1’ and 72°C for 70”, with an extension
at 72°C for 10’. Three microliters from the first PCR reac-
tion were used in the nested PCR with the following condi-
tions: denaturation step at 94°C for 10’ and then 30 cycles
at 94°C for 1’, 52°C for 1’ and 72°C for 70”, with an exten-
sion at 72°C for 10’.
Direct sequencing of PCR products was performed using
an automatic sequencer (ABI PRISM 3100 genetic analyzer
DNA Sequencer, Applied Biosystems, Foster City, CA,
USA) and the BigDye Terminator v1.1 Cycle Sequencing
kit (Applied Biosystems, Foster City, CA, USA).
Only variants present in more than 5% of the patient
virus populations for each HCV genotype group were
considered in the genotypic resistance analysis [12].
Nucleotide sequences were assembled using the Se-
quencer 4.6 (Gene Codes Corp., Ann Arbor, MI) soft-
ware program. To obtain a detailed subtyping of HCV
strains, nucleotide sequences were aligned with con-
firmed references of different subtypes using the Clus-
talW method which is embedded in the Mega 5
package [20].
The phylogeny of the sequences was constructed using
the Neighbour Joining method. The nucleotide substitu-
tion model was selected according to Akaike Informa-
tion Criterion scores. A Neighbour Joining tree was
constructed with MEGA 5 software [20] setting the
Tamura 3-parameter as an evolutionary model with an
heterogeneous rate among sites using gamma distribu-
tion for the relative rate. Branch support was assessed by
bootstrap analysis with 1000 replicates. Bootstrap values
of 70% were used as the cut off point for cluster analysis.
The sequences reported in this study have been submit-
ted to the GenBank database under accession numbers
J × 170910 to J × 171065.
The GenBank accession numbers for reference
sequences used to determine the HCV genotypes were as
follows: M62321 (subtype 1a), NC004102 (subtype 1a;
H77-US1977), D90208 (subtype 1b), D14853 (subtype 1c),
D00944 (subtype 2a), D10988 (subtype 2b), D50409 (sub-
type 2c), AB031663 (subtype 2 k), D17763 (subtype 3a),
D49374 (subtype 3b), D63821 (subtype 3 k), Y11604 (sub-
type 4a), GU085486 (subtype 4a), FJ025855 (subtype 4b),
FJ025854 (subtype 4b), FJ462436 (subtype 4c) FJ462437
(subtype 4d), EU392172 (subtype 4d), EU392170 (subtype
4f), FJ462432 (subtype 4 g), FJ462438 (subtype 4 k),
EU392171 (subtype 4 k) EU392173 (subtype 4 k), FJ839870
(subtype 4 l), FJ462433 (subtype 4 m), FJ462441 (subtype
4n), FJ462440 (subtype 4o), FJ462431 (subtype 4p),
FJ462434 (subtype 4q) FJ462439 (subtype 4r) FJ839869
(subtype 4 t), Y13184 (subtype 5a), Y12083 (subtype 6a),
D84262 (subtype 6b), D84263 (subtype 6d), D63822 (sub-
type 6 g), D84265 (subtype 6 h), D84264 (subtype 6 k).
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The clinical and virologic characteristics of patients consid-
ered in the study are provided in Table 1. Fifteen patients
(9.5%) were co-infected with HIV and treated with highly
active antiretroviral therapy (HAART) (Table 1).
Aa substitutions associated with HCV PI resistance
were found in 50/156 (32%) sequences of PI naïve HCV
patients (Table 2). Mutations V36L, T54S, V55A/I, and
Q80K/L were observed in 29% of patients with genotype
1a, and V55F, Q80L/N and M175L in 10% of patients
with genotype 1b. Mutation V158M was found in 3%
patients with genotype 2, D168Q was present in 100%
pts with genotype 3 and D168E was observed in 13% of
patients with genotype 4 (Table 2). In addition, multiple
aa polymorphisms not associated with PI resistance were
detected in all genotypes (Table 2).
Amino acids at positions S138 and V170 reported to
be correlated with PI resistance when there is a change
from T to T/A [7], respectively, changed to S138C and
V170I in patients with genotype 1b were not associated
with PI resistance. In addition, all sequences of geno-
types 2, 3 and 4 showed the mutation V36L which has
been associated with PI resistance in HCV patients with
genotype 1. Of note, HCV PI resistance mutations in
HCV/HIV co-infected patients were found in only one
patient (Q80L).
A mutation at position 176 (S176N) different from
that previously correlated with resistance (S176G) [11]
was found in four patients with genotype 3. Previously
reported [10] compensatory aa changes (I71V, I72T/F,
and Q86P) were observed in both genotypes 1a and 1b.
In individual genotype 1b strains, the resistance muta-
tion V55F was associated with compensatory mutation
T72I, mutation Q80L/N was associated with Q86P and
mutation M175L was associated with T72I and Q86P. In
contrast, the two compensatory mutations in genotype
1a were detected in the absence of resistance mutations.Table 1 Patient characteristics by HCV genotype
Characteristic
1a (n = 31) 1b (n = 39)
Gender
Male 26 (83%) 20 (51%)
Female 5 (27%) 19 (49%)
Race
Italian 29 (93%) 38 (97%)
Others 2 (7%) 1 (3%)
No. of patients HIV-1 co-infected
receiving HAART (%)
5 1
Median HCV viral load (IU/mL log10)
in HCV mono-infected pts
5.66 (range 3.03-6.44) 5.63 (range 4.2-6
Median HCV viral load (IU/mL log10)
in HCV/HIV co-infected pts
6.41 (range 4.73-6.77) 5.95Finally, a number of polymorphisms not associated with
PI resistance, were detected between codon 4 and codon
179 in all genotypes (Table 3). In genotypes 1a, 1b and 4
multiple polymorphisms (4, 15 and 29, respectively)
were detected, while 11 and 17 polymorphisms were
found in genotypes 2 and 3, respectively. In detail, the
number of aa changes for each natural polymorphic site
in the different genotypes was 104 in genotype 1a, 186
in genotype 1b, 84 in genotype 2, 97 in genotype 3 and
255 in genotype 4.
The mean genetic diversity of NS3 was higher in geno-
type 4 (16.6%) than in genotype 1b (12.0%), 1a (10.4%), 2
(11.2%), and 3 (9.2%). Among patients infected with
HCV genotype 1, sequences were equally distributed in
HCV subtypes 1a and 1b. The number of sequences car-
rying mutations associated with PI resistance was 2-fold
higher in subtype 1a with respect to subtype 1b (p =
0.07) (Figure 1). All sequences clustering within geno-
type 2, belonged to subtype 2c and only one sequence
carried a mutation correlated with resistance. All
sequences from patients infected with genotype 3 clus-
tered in the subtype 3a, and all sequences showed the
D168Q change (Figure 1). Among the HCV genotype 4
sequences, 14/23 (60.9%) belonged to subtype 4d, while,
6/23 (26.1%) were subtype 4a, 1/23 (4.3%) was subtype
4c and 2/23 (8.7%) clustered together with an uncom-
mon subtype (Figure 1). Among these, one sequence
exhibited 91.6% identity with HCV subtype 4 m, and the
second exhibited 89.1% identity with HCV subtype 4 t
(bootstrap value >99%) (Figure 1).
All HCV/HIV co-infected patients with genotype 4
clustered in the subtype 4c, while the mutations corre-
lated with PI resistance were observed both in subtype
4c and subtype 4a (Figure 1). In particular, a mutation
associated with PI resistance (D168E) was observed in
two identical sequences (4-6706 m11 and 4-5208 m11)
from different patients.HCV genotype
2 (n = 30) 3 (n = 33) 4 (n = 23)
11 (36%) 26 (78%) 17 (85%)
19 (64%) 7 (22%) 3 (15%)
30 (100%) 31 (93%) 13 (65%)
0 2 (7%) 7 (35%)
0 4 4
.75) 5.96 (range 3.6-6.84) 5.38 (range 2.97-6.58) 5.66 (range 2.40-6.78)
0 6.54 (range 6.17-6.86) 6.45 (range 6.42-6.52)
Table 2 Amino acid variations in the HCV NS3 protein associated with resistance mutations to HCV NS3 protease




HCV variation in different genotypes (number of sequenced patients)b
1a 1b 2 3 4
(n = 31) (n = 39) (n = 30) (n = 33) (n = 23)
36 (R) V36Lc (2) e V36 L36 L36 L36
41 (R) Q41 Q41 Q41 Q41 Q41
43 (R) F43 F43 F43 F43 F43
54 (R) T54S (2) e T54 T54 T54 T54
55 (R) V55A/I (2) e V55F (1) e V55 V55 V55
79 (R) D79 D79 E79 D79 D79
80 (R) Q80K/L (3) e Q80L/N (2) e G80 Q80 Q80
109 (R) R109 R109 R109 R109 R109
138 (R) S138 S138C (1)d S138 S138 S138
155 (R) R155 R155 R155 R155 R155
156 (R) A156 A156 A156 A156 A156
158 (R) V158 V158 V158M (1) e V158 V158
168 (R) D168 D168 D168 D168Q (33) e D168E (3) e
170 (R) I170 V170I (12)d I170 I170V (1)d V170
175 (R) L175 M175L (1) e L175 L175 L175
176 (R) E176 E176 D176 S176N (4)d E176
71 (C) V71 I71V/L (5) e V71 A71S (1)d V71
72 (C) I72T/F (2) e T72I/A/L (11) e T72 L72F (1)d N72C (2)d
86 (C) P86 Q86P (6) e P86S (1)d P86S (2)d P86
88 (C) P88 P88 P88 P88 P88
aR, position associated with primary resistance; C, position associated with compensatory mutations; (Lopez, 2008; Flint, 2009; Susser, 2009; Lentz, 2010; Verbimen,
2010; Romano, 2010, Halfon, 2011).
bReference strains for each genotype: M62321 (1a), D90208 (1b), D50409 (2c), D17763 (3a), and Y11604 (4a).
cLetter on the left represents the wild type amino acid, on the right, the amino acid substitution. The number of patients with mutant HCV strains is indicated in
brackets.
dPolymorphism with no associated resistance.
e Amino acid changes conferring resistance are reported in bold.
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The identification of baseline resistance mutations to
anti-HCV PIs is crucial for defining new therapeutic
approaches. Natural polymorphisms in the HCV NS3/
4A protease-coding region were analyzed in 156 patients
including genotypes 1a, 1b, 2, 3, and 4. Relevant natural
aa polymorphisms were found among the different geno-
types and subtypes. The data presented are important
not only to determine whether PI-resistant mutants are
likely to be present in PI treatment-naïve patients, but
also for the examination of HCV protease among differ-
ent genotypes and the possibility of eventually extending
the PI treatment to non-genotype 1-infected patients.
On the other hand, the study of preexisting viral variants
to predict response to PIs for genotypes other than 1
might be misleading, since the molecular target struc-
ture could be considerably different between genotype 1
HCV and other genotypes. In fact, all recent clinical
trials have been designed for treatment of HCVinfections with genotype 1 [5,6,21]. Although culture
systems for determining HCV susceptibility to PI com-
pounds have been recently developed [4], the compara-
tive genetic analysis of HCV strains in PI naïve patients
infected with different virus genotypes may provide in-
formation useful for predicting treatment efficacy since,
naturally occurring genotype-specific variations appear
to have an effect in different HCV genotypes [22,23]. In
addition, even though resistant viral variants exist at low
frequency in untreated patients, specific NS3 protease
mutations may have an important role in modulating re-
sistance development and modifying viral fitness [22].
Substitutions at positions R155 and A156, which are
known to confer a high level of resistance to all PIs [7,9],
were not observed in our patients. In contrast, other
minor mutations conferring low levels of resistance to
PIs [7,9,14,22] were found in 32% of patients. In
addition, all sequences from genotypes 2, 3 and 4
showed the V36L mutation which is known to confer































4 T4P (14) 67 S67P/A (14) A67V/T (7)
5 A5T/P (3) A5G/C(6) 69 H69R (2)
7 S7A (12) A7T/V
(11)
A7T(2) 72 I72T/F (2) T72A/I/L
(13)
10 T10H/N (2) 82 L82G (3)
11 R11P (2) 83 V83N/T/I
12 G12A/R (3) 91 S91A/T (28) A91S (5) A91T (4)
13 L13M/W/T
(13)
92 T95E/S (2) R92K/T (15)
14 L14F (5) L14F (3) F14L/I (15) 95 E95D (3) A95T/S (4)
15 D15G
(28)
S15G (12) 98 A/98 T (15)
16 A16T (8) 101 S101A (8)
18 I18V (2) I18V (4) V18I (3) 102 S102A (3) A102S (20)
20 S20G (4) 105 Y105F (14)
24 R24K (2) R24K (3) 107 V107I (4)





114 I114V (3) V114I (26) I114V (18)
33 V33I (2) V33I (10) V33I (13) 117 R117H/C (4)
35 V35I (5) V35I (3) 119 R119Q
(2)




42 S42T/F (5) 127 L127I (11)
44 L44M (2) 132 I132V/M
(18)
L132I (2)
46 T46S/A (2) 134 S134T
(13)
47 A47G/S (2) 146 P146S (2)




49 N49S (2) 150 V150A (29) R150V/A (20)
51 V51A (2) V51T/A
(3)
151 A151V (3)




61 T61S (2) K61R (4) 174 N174S/G
(23)
S174A/L (3) S174T (2)
64 I64L (2) 177 V177I (3)
65 S65C (2) 179 A179T/V (2)
aAmino acid position associated with polymorphisms compared to reference sequences;
bReference strain accession numbers for each genotype: M62321 (1a), D90208 (1b), D50409 (2c), D17763 (3a), and Y11604 (4a).
cLetter on the left represents the wild type amino acid, on the right, the amino acid substitution. The number of patients with mutant HCV strains is indicated in brackets.
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Figure 1 Phylogenetic analysis of HCV protease in PI-naïve patients. Black circles ● indicate available reference sequences; grey triangles▲,
protease baseline resistant patients; white squares □, HIV co-infected patients.
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sequences from genotype 3 showed the D168Q mutation
which is known to decrease the activity of non-covalent
HCV NS3 protease inhibitors against genotype 3 (4, 14).
Moreover, a higher number of polymorphic sites in
HCV protease NS3/4A were observed in genotypes 1b
and 4 compared with genotypes 1a, 2 and 3. Further
studies are needed to better understand the potential
implications on treatment of PI naïve patients with re-
sistance at baseline which could influence the treatment
failure rate. On the other hand the clinical role of com-
pensatory mutations impacting the viral fitness of PI re-
sistant strains [25-27] requires additional investigation.In contrast with reported observations [28], HCV PI
resistance mutations were not observed more frequently
in HCV/HIV co-infected patients than HCV mono-
infected patients. Phylogenetic analysis confirmed the
greater heterogeneity of HCV genotypes 1b and 4, which
may be explained by the presence of several divergent
sequences with respect to other genotypes. In keeping
with data from the Italian HCV genotype distribution
[29], subtype 4d strains were observed also in our series.
In this data set, a wide distribution of mutations correl-
ating with PI resistance was observed in all genotypes. A
larger data set of HCV sequences including baseline data
would clarify this finding.
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populations (HIV co-infected or mono-infected)
observed in our study confirms [30-32] and underlines
their potential implication in the management of HCV
treatment; ii) no major mutations associated with resist-
ance to PIs were observed in HCV PI naïve patients, on
the contrary, a consistent number of minor mutations
which may reduce the efficacy of PIs were detected in
genotypes 1a, 1b and also in genotypes 2, 3 and 4. Thus,
the inclusion of patients with different genotypes in fu-
ture larger clinical trials, would help define the efficacy
of anti HCV PIs in patients infected with different geno-
types and these data could be extended to design treat-
ment protocols. In addition, further investigations are
necessary to understand the utility of resistance analysis
at baseline to evaluate response to HCV protease
inhibitors.
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